Corvus Pharmaceuticals(CRVS) - 2024 Q1 - Quarterly Results

EXHIBIT 99.1 Financial Results Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Conference call today at 4:30 p.m. ET / 1:30 p.m. PT "We continue to make strong progress with our two key priorities for the year – advancing soquelitinib for PTCL and generating early data for soquelitinib for atopic dermatitis," said Richard A. Miller, M.D., cofounder, president and chief executive officer of Corvus. "We are encouraged that two newly evaluabl ...